Experienced in Neurofibromatosis Type 1 (NF1)
Experienced in Neurofibromatosis Type 1 (NF1)
Children's Health Care
2525 Chicago Ave, 
Minneapolis, MN 

Overview

Michael Richards is a Pediatrics specialist and a Pediatric Hematologist Oncology provider in Minneapolis, Minnesota. Dr. Richards is rated as an Experienced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Langerhans Cell Histiocytosis, Hepatoblastoma, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration. Dr. Richards is currently accepting new patients.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 56 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Neurofibromatosis Type 1 (NF1).

Specialties
Pediatrics
Pediatric Hematology Oncology
Licenses
Pediatrics in MN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 8 Less Insurance Carriers -

Locations

CHILDREN'S HEALTH CARE
2525 Chicago Ave, Minneapolis, MN 55404

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


56 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
View 49 Less Clinical Trials
Similar Doctors
Elite in Neurofibromatosis Type 1 (NF1)
Pediatric Hematology Oncology
Elite in Neurofibromatosis Type 1 (NF1)
Pediatric Hematology Oncology

Fairview Express Care

2450 Riverside Ave, 
Minneapolis, MN 
 (1.4 miles away)
Languages Spoken:
English

Christopher Moertel is a Pediatric Hematologist Oncology provider in Minneapolis, Minnesota. Dr. Moertel is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, and RASopathies.

Experienced in Neurofibromatosis Type 1 (NF1)
Pediatric Hematology Oncology
Experienced in Neurofibromatosis Type 1 (NF1)
Pediatric Hematology Oncology

Fairview Express Care

2450 Riverside Ave, 
Minneapolis, MN 
 (1.4 miles away)
Experience:
9+ years
Languages Spoken:
English

Robert Galvin is a Pediatric Hematologist Oncology provider in Minneapolis, Minnesota. Dr. Galvin has been practicing medicine for over 9 years and is rated as an Experienced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Glioma, and Malignant Peripheral Nerve Sheath Tumor.

Experienced in Neurofibromatosis Type 1 (NF1)
Medical Genetics | Pediatrics
Experienced in Neurofibromatosis Type 1 (NF1)
Medical Genetics | Pediatrics
2525 Chicago Ave S, 
Minneapolis, MN 
 (0.1 miles away)
Languages Spoken:
English

Amy Lebedoff is a Medical Genetics specialist and a Pediatrics provider in Minneapolis, Minnesota. Dr. Lebedoff is rated as an Experienced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). Her top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Increased Head Circumference, and Marshall-Smith Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Richards's expertise for a condition
ConditionClose
      View All 14 Advanced Conditions
      View All 13 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile